Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 946.30, down by 34.70 points or 3.54% from its previous closing of Rs. 981.00 on the BSE.

The scrip opened at Rs. 933.70 and has touched a high and low of Rs. 963.00 and Rs. 916.00 respectively. So far 223605 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1085.40 on 30-May-2013 and a 52 week low of Rs. 579.10 on 13-Jun-2012.

Last one week high and low of the scrip stood at Rs. 1039.00 and Rs. 916.00 respectively. The current market cap of the company is Rs. 98918.79 crore.

The promoters holding in the company stood at 63.68% while Institutions and Non-Institutions held 26.00% and 10.32% respectively.

Sun Pharmaceutical Industries, along with its subsidiaries, has settled an ongoing litigation pending in the United States District Court, District of New Jersey (Court) regarding Sun Pharma subsidiary’s generic pantoprazole.

Under the terms of the litigation settlement between Sun Pharma and Wyeth, now a division of Pfizer Inc and Atlanta Pharma AG, now known as Takeda GmbH, the parties have dismissed all their claims. Sun Pharma will pay a lump-sum $550 million as a part of this settlement. It will continue to sell its generic pantoprazole in the U.S.

Sun Pharmaceuticals Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.